Mortality Attributable to Bloodstream Infections Caused by Different Carbapenem-Resistant Gram-Negative Bacilli: Results From a Nationwide Study in Italy (ALARICO Network)
- Authors: Falcone, Marco; Tiseo, Giusy; Carbonara, Sergio; Marino, Andrea; Di Caprio, Giovanni; Carretta, Anna; Mularoni, Alessandra; Mariani, Michele Fabiano; Maraolo, Alberto Enrico; Scotto, Riccardo; Dalfino, Lidia; Corbo, Lorenzo; Macera, Margherita; Medaglia, Alice Annalisa; d'Errico, Maria Luca; Gioè, Claudia; Sgroi, Christian; Del Vecchio, Rosa Fontana; Ceccarelli, Giancarlo; Albanese, Antonio; Buscemi, Calogero; Talamanca, Simona; Raponi, Giammarco; Foti, Giuseppe; De Stefano, Giulio; Franco, Antonina; Iacobello, Carmelo; Corrao, Salvatore; Morana, Uccio; Pieralli, Filippo; Gentile, Ivan; Santantonio, Teresa; Cascio, Antonio; Coppola, Nicola; Cacopardo, Bruno; Farcomeni, Alessio; Venditti, Mario; Menichetti, Francesco
- Publication year: 2023
- Type: Articolo in rivista
- OA Link: http://hdl.handle.net/10447/620120
Abstract
Background. Our aim was to analyze mortality attributable to carbapenem-resistant (CR) gram-negative bacilli (GNB) in patients with bloodstream infections (BSIs).Methods. Prospective multicentric study including patients with GNB-BSI from 19 Italian hospitals (June 2018-January 2020). Patients were followed-up to 30 days. Primary outcomes were 30-day mortality and attributable mortality. Attributable mortality was calculated in the following groups: Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacterales, metallo-beta-lactamases (MBL)-producing Enterobacterales, CR-Pseudomonas aeruginosa (CRPA), CR-Acinetobacter baumannii (CRAB). A multivariable analysis with hospital fixed-effect was built to identify factors associated with 30-day mortality. Adjusted OR (aORs) were reported. Attributable mortality was calculated according to the DRIVE-AB Consortium.Results. Overall, 1276 patients with monomicrobial GNB BSI were included: 723/1276 (56.7%) carbapenem-susceptible (CS)GNB, 304/1276 (23.8%) KPC-, 77/1276 (6%) MBL-producing CRE, 61/1276 (4.8%) CRPA, and 111/1276 (8.7%) CRAB BSI. Thirty-day mortality in patients with CS-GNB BSI was 13.7% compared to 26.6%, 36.4%, 32.8% and 43.2% in patients with BSI by KPC-CRE, MBL-CRE, CRPA and CRAB, respectively (P <.001). On multivariable analysis, age, ward of hospitalization, SOFA score, and Charlson Index were factors associated with 30-day mortality, while urinary source of infection and early appropriate therapy resulted protective factors. Compared to CS-GNB, MBL-producing CRE (aOR 5.86, 95% CI 2.72-12.76), CRPA (aOR 1.99, 95% CI 1.48-5.95) and CRAB (aOR 2.65, 95% CI 1.52-4.61) were significantly associated with 30-day mortality. Attributable mortality rates were 5% for KPC-, 35% for MBL, 19% for CRPA, and 16% for CRAB.Conclusions. In patients with BSIs, carbapenem-resistance is associated with an excess of mortality, with MBL-producing CRE carrying the highest risk of death.